Watchlist Price Alert

Xencor Inc. (XNCR)

NASDAQ: XNCR · Real-Time Price · USD

8.16

0.05 (0.62%)

At close: May 14, 2025, 3:59 PM

8.00

-1.96%

Pre-market: May 15, 2025, 07:00 AM EDT

0.62% (1D)

Bid	7.99
Market Cap	580.75M
Revenue (ttm)	130.42M
Net Income (ttm)	-213M
EPS (ttm)	-3.04
PE Ratio (ttm)	-2.68
Forward PE	-3.43
Analyst	Buy

Ask	9.14
Volume	949,179
Avg. Volume (20D)	883,148
Open	8.16
Previous Close	8.11
Day's Range	7.90 - 8.35
52-Week Range	7.16 - 27.24
Beta	0.99

About XNCR

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol XNCR

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for XNCR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Xencor has released their quartely earnings on May 7, 2025:

Revenue of $32.73M exceeds estimates by $9.29M, with 155.62% YoY growth.

EPS of -0.66 misses estimates by -0.09, with 40.54% YoY growth.

Why Price Moved

1 week ago

-21.08%

Shares of vaccine and gene therapy stocks are trad... Unlock content with Pro Subscription

8 months ago

+10.45%

Xencor shares are trading higher. The company priced its $175 million offering of 6.635 million shares of its common stock at $18.00 per share.

News

1 week ago · zacks.com

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

Xencor (XNCR) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $1.11 per share a year ago.

1 week ago · businesswire.com

Xencor Reports First Quarter 2025 Financial Results

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today re...

2 weeks ago · zacks.com

Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago · zacks.com

Xencor (XNCR) Upgraded to Buy: Here's Why

Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · zacks.com

Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates

Xencor (XNCR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.31 per share a year ago.

2 months ago · businesswire.com

Xencor Reports Fourth Quarter and Full Year 2024 Financial Results